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ORIGINAL ARTICLE

Abnormal metabolic pattern associated with cognitive
impairment in Parkinson’s disease: a validation study
Sanne K Meles1, Chris C Tang2, Laura K Teune1, Rudi A Dierckx3, Vijay Dhawan2, Paul J Mattis2, Klaus L Leenders1 and David Eidelberg2
Cognitive deﬁcits in Parkinson’s disease (PD) have been associated with a speciﬁc metabolic covariance pattern. Although the
expression of this PD cognition-related pattern (PDCP) correlates with neuropsychological performance, it is not known whether
the PDCP topography is reproducible across PD populations. We therefore sought to identify a PDCP topography in a new sample
comprised of 19 Dutch PD subjects. Network analysis of metabolic scans from these individuals revealed a signiﬁcant PDCP
that resembled the original network topography. Expression values for the new PDCP correlated (P = 0.001) with executive
dysfunction on the Frontal Assessment Battery (FAB). Subject scores for the new PDCP correlated (P o0.001) with corresponding
values for the original pattern, which also correlated (P o0.005) with FAB scores in this patient group. For further validation, subject
scores for the new PDCP were computed in an independent group of 86 American PD patients. In this cohort, subject scores for
the new and original PDCP topographies were closely correlated (P o 0.001); signiﬁcant correlations between pattern expression
and cognitive performance (P o 0.05) were observed for both PDCP topographies. These ﬁndings suggest that the PDCP is a
replicable imaging marker of PD cognitive dysfunction.
Journal of Cerebral Blood Flow & Metabolism (2015) 35, 1478–1484; doi:10.1038/jcbfm.2015.112; published online 10 June 2015
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INTRODUCTION
Parkinson’s disease (PD) is primarily a disorder of movement
caused by dopaminergic attrition in the substantia nigra. Nonetheless, over the past decade, this disease has been associated
with non-motor manifestations, represented most prominently by
cognitive decline.1 Indeed, with improved treatment of motor
symptoms, cognitive difﬁculties are increasingly regarded as a
major factor determining functional outcome and quality of life in
PD patients.2–4 The earliest cognitive deﬁcit observed in PD is the
development of executive dysfunction before the onset of actual
dementia. In fact, such changes have been documented in newly
diagnosed patients with early motor symptoms.5 Cognitive
dysfunction in PD begins with mild cognitive impairment (MCI)
affecting a single behavioral domain, followed by involvement of
multiple domains, such as visuospatial and memory performance.
These changes ultimately lead to dementia, which is 4–6 times
more likely to occur in PD patients compared with the healthy
aged population.6,7 The precise mechanisms underlying the
development and progression of cognitive dysfunction in PD are
largely unknown. Performance on standardized neuropsychological testing batteries is considered to be the ‘gold standard’ for the
assessment of cognitive dysfunction in PD patients. Nonetheless,
the assessment of changes in cognitive function over time
remains challenging in PD, especially at the individual subject
level. Additional quantitative descriptors of cognitive dysfunction
in PD patients may be particularly relevant in clinical trials to
evaluate new therapies for this debilitating symptom of the
disease. Metabolic imaging with 18F-ﬂuorodeoxyglucose (FDG)
positron emission tomography (PET) has been used to study the
1

systems-level changes in brain function that underlie PD and
related movement disorders.8–11 Spatial covariance mapping
approaches8,12,13 have been applied to resting-state metabolic
brain images to identify and validate characteristic disease-related
regional patterns associated with PD.14 The metabolic topography
of the abnormal PD motor-related pattern, associated primarily
with akinetic-rigid disease manifestations,15 has been extensively
replicated in FDG PET scans from multiple populations of patients
and control subjects.9,16
Using a similar method, we have also identiﬁed a separate
pattern associated with cognitive symptoms in non-demented PD
patients. This PD cognition-related pattern (PDCP)17 has been found
to correlate with performance on neuropsychological tests of
executive function in several independent patient samples.8,17–19
Importantly, PDCP subject scores, which denote the expression of
the pattern in individual patients, exhibited excellent reproducibility
on test–retest evaluation.17 This justiﬁes further exploration of
the measure as a potential descriptor of the effects of disease
progression and treatment on cognition-related metabolic
pathways.18–20 That said, presently data do not exist concerning
the replicability of the PDCP topography itself across derivation
samples. In the current study, we identiﬁed a PDCP in FDG PET
data from an independent PD derivation sample scanned in the
Netherlands. The topography of this spatial covariance pattern was
compared with that of the original PDCP, which was previously
derived from FDG PET data of a PD cohort scanned in the United
States.17 We also compared correlations between expression values
for the two PDCP topographies and cognitive performance in the
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present Dutch sample and in a large previously reported American
testing set.21
MATERIALS AND METHODS
Subjects

Network Analysis

We studied 19 early-stage PD patients (age 63.7 ± 7.7 years; disease
duration 4.4 ± 3.2 years; motor Uniﬁed Parkinson’s Disease Rating Scale
18.4 ± 7.4) and 17 age-matched healthy volunteer subjects (age 61.1 ± 7.4
years) (Table 1A), who underwent metabolic brain imaging in the resting
state with FDG PET at the University Medical Center Groningen, the
Netherlands. The details of the scanning procedures are provided
elsewhere.16 Executive function was assessed in the PD and healthy
volunteer subjects using the Frontal Assessment Battery (FAB)22 administered the same day as the PET study. All subjects were non-demented, as
deﬁned by a cutoff Mini Mental State Examination (MMSE) score of 24
(MMSE for PD subjects 28.5 ± 1.1, range 26–30; MMSE for control subjects
29.4 ± 0.9, range 27–30). Network analysis was applied using the imaging
and cognitive test data from this cohort (see below) to identify a new PDCP
topography (termed PDCP Groningen or PDCPGR).
For testing, we measured the expression of the new PDCPGR pattern in an
independent group of 86 non-demented PD subjects (age 60.8 ± 8.2 years;
disease duration 12.5 ± 5.9 years; motor Uniﬁed Parkinson’s Disease Rating
Scale 31.6 ± 14.4; MMSE 28.0 ± 1.4, range 25–30; Table 1B) who were
scanned at North Shore University Hospital, Manhasset, NY, USA as
described previously.21 Subjects in this cohort were assessed according to
a comprehensive neuropsychological testing battery23–28 as being cognitively unimpaired (MCI(−), n = 20) or as having either single- (MCI(s), n = 34)
or multiple-domain (MCI(m), n = 32) MCI; 15 age-matched healthy volunteer
subjects (age 56.7 ±12.3 years) provided reference values for this cohort.

Image Acquisition and Preprocessing
All subjects were scanned with FDG PET under resting conditions. All
antiparkinsonian medications were withheld at least 12 h before imaging.
In the Groningen sample, PET imaging was performed using the Siemens
Biograph mCT-64 scanner (Siemens Healthcare, Knoxville, TN, USA) (5 mm
full width half maximum) at the University Medical Center Groningen.16 In
the North Shore sample, scanning was performed using the GE Advance
tomograph (GE Healthcare, Milwaukee, WI, USA) (4.0 mm full width half
maximum) at the North Shore University Hospital.17 Scans from each
subject were realigned and spatially normalized to a standard Talairachbased FDG PET template and smoothed with an isotropic Gaussian kernel
(10 mm). All image processing was performed using Statistical Parametric
Mapping (SPM5) software (Wellcome Department of Cognitive Neurology,
London, UK) running in MATLAB 7.5 (MathWorks, Natick, MA, USA).
Ethical permission for the procedures was obtained from the ethics
committee at the University Medical Center Groningen (Groningen, the

Table 1.

Netherlands) and from the Institutional Review Board of the North Shore
University Hospital (Manhasset, NY, USA). Written consent was obtained at
each institution from all subjects following a detailed explanation of the
testing procedures.

Spatial covariance analysis was performed on scans from the Groningen PD
subjects using an automated voxel-based algorithm (available at http://
feinsteinneuroscience.org). The details of this approach are provided
elsewhere.8,12,13 Before performing principal component (PC) analysis on
the images, logarithmically transformed scan data from the subjects were
orthogonalized to the PD motor-related topography that was previously
identiﬁed in this population.16 This procedure was used to minimize
extraneous motor-related network effects in the PDCP derivation.29 Spatial
covariance analysis was applied to the residual data in the orthogonal ‘nonmotor’ subspace to identify speciﬁc topographic patterns that, if present,
correlated with quantitative indices of cognitive performance in these
subjects. The details of the procedures used to identify PDCP topographies
have appeared previously.17 In the current study, the PDCP topography was
sought among the PCs that accounted for the top 50% of the variance in the
data. Subject scores for these PCs (denoting the expression of each linearly
independent pattern in the individual subjects) were entered into a linear
regression model to predict executive functioning as measured by FAB
scores. A resulting pattern was considered cognition-related if the associated
subject scores correlated signiﬁcantly with FAB at Po0.01. Voxel weights
(loadings) on the pattern were thresholded at Z = 1.96, which corresponded
to a signiﬁcant regional contribution (Po0.05) to overall network activity,
and further tested for reliability using a bootstrap resampling procedure.30
The signiﬁcant clusters were reported in standard space; corresponding
brain regions were localized according to the atlas of Talairach31 and, for the
cerebellum, the atlas of Schmahmann.32
In addition to subject scores for the new PDCPGR pattern, we also
measured the expression values for the PDCPNS topography that was
identiﬁed in the original North Shore PD cohort. Both sets of PDCP subject
scores were standardized by z-transformation with respect to corresponding values from normal subjects scanned at Groningen so that this control
group had a mean expression of zero with an s.d. of one.12 Subject scores
for the two patterns were tested for intercorrelation in members of the
Groningen PD derivation sample. Additionally, correlations with FAB scores
were separately assessed for each set of PDCP subject scores obtained in
this group. Correlations were considered signiﬁcant for Po 0.05, Pearson
product-moment correlation coefﬁcient.

PDCP Expression Across PD Subgroups and Neuropsychological
Correlations
PDCPGR subject scores were also computed on a prospective single case
basis in members of the North Shore testing sample. PD patients in this

Demographic data of the Groningen and North Shore PD cohorts
HC

PD

P-valuea

A. Groningen sample for derivation of PDCPGR
Number of subjects
Gender, F/M
Age, years
Disease duration, years
UPDRS (off-state motor)
MMSE
FAB

17
5/12
61.1 ± 7.4 (51.5–78)b
NA
NA
29.4 ± 0.9 (27–30)
17.5 ± 0.8 (15–18)

19
6/13
63.7 ± 7.7 (49–76)
4.4 ± 3.2 (1.5–11.5)
18.4 ± 7.4 (9–32)
28.5 ± 1.1 (26–30)
15.7 ± 1.9 (11–18)

—
0.89
0.3
—
—
0.01
0.001

B. North Shore testing sample
Number of subjects
Gender, F/M
Age, years
Disease duration, years
UPDRS (off-state motor)
MMSE

15
7/8
56.7 ± 12.3 (37–76.8)
NA
NA
NA

86
27/59
60.8 ± 8.2 (37–77)
12.5 ± 5.9 (4–32)
31.6 ± 14.4 (10–67)
28.0 ± 1.4 (25–30)

—
0.25
0.23
—
—
—

Abbreviations: F, female; FAB, Frontal Assessment Battery; HC, healthy controls; M, male; MMSE, Mini Mental State Examination; PD, Parkinson's disease;
PDCPGR, Groningen PD cognition-related pattern; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale. aχ2 test for gender; two sample t-test for age;
Mann–Whitney U-test for MMSE and FAB. bData are shown as mean ± s.d. (range).

© 2015 ISCBFM
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Figure 1. (A) Parkinson’s disease (PD)-related cognitive pattern (PDCPGR) derived by spatial covariance analysis of 18F-ﬂuorodeoxyglucose
positron emission tomographic scans from the Groningen cohort of 19 PD patients. This pattern was characterized by metabolic decreases in
the caudate nucleus, thalamus and presupplementary motor area (preSMA), posterior cingulate cortex and parietal regions, with metabolic
increases in the cerebellum (lobule VI/Crus I) and anterior cingulate cortex. (Voxels with negative region weights (metabolic decreases) are
color-coded blue and those with positive region weights (metabolic increases) are color-coded red. The regions shown represent those that
contributed signiﬁcantly to the network, displayed at Z = 2.44 (Po0.01) for blue regions and at Z = 1.96 (P o0.05) for red regions and were
demonstrated to be reliable (P o0.01; 1000 iterations) by bootstrap resampling. Left hemisphere was labeled as ‘L’.) (B) In the 19 PD subjects,
PDCPGR expression exhibited a signiﬁcant correlation (r = −0.72, P = 0.001) with Frontal Assessment Battery (FAB) scores. (C) Likewise, the
expression of the original PD-related cognitive pattern (PDCPNS) previously derived from the North Shore sample also correlated signiﬁcantly
(r = − 0.63, P o0.005) with FAB scores measured in the same 19 PD patients. BA, Brodmann area.

cohort were divided into prespeciﬁed MCI(−), MCI(s) and MCI(m) categories
based upon individual neuropsychological test performance (see above).
Differences in pattern expression across these subgroups were assessed
using one-way analysis of variance and post-hoc Tukey–Kramer Honest
Signiﬁcant Difference (HSD) tests.
In addition, we computed the original PDCPNS subject scores in the
testing data and correlated the expression values of the two PDCP networks
in this group. We also examined relationships between PDCPGR and PDCPNS
subject scores and performance on the Symbol Digit Modalities Test (SDMT),
Hooper Visual Organization Test (HVOT), California Verbal Learning Test and
Trail Making Test A (TMT A) and B (TMT B) tests, consistently correlating
with network expression in previous studies.17,19,21 Network–performance
correlations were reported as Pearson product-moment coefﬁcients with
uncorrected P-values.
Statistical analyses were performed in SPSS 14.0 (SPSS Inc., Chicago, IL,
USA) and were considered signiﬁcant for Po 0.05.

RESULTS
Characterization of the PDCPGR Topography
Spatial covariance analysis was performed on the scan data from
the 19 PD subjects that comprised the Groningen derivation
sample. This analysis yielded ﬁve linearly independent (orthogonal)
PCs, which together accounted for 55% of the total subject × voxel
variance. The ﬁrst PC (Figure 1A), which accounted for 19.6% of the
total variance, was the only one of the top ﬁve PCs that exhibited a
signiﬁcant correlation (r = −0.72, P = 0.001) between its expression
(subject scores) in the individual members of the derivation sample
and corresponding cognitive ratings (FAB scores) obtained in the
same subjects at the time of imaging (Figure 1B). Indeed, FAB
scores in the PD patients were lower (P = 0.001, Mann–Whitney
U-test) than for the 17 healthy subjects in the same population; the
Journal of Cerebral Blood Flow & Metabolism (2015), 1478 – 1484

Table 2. Brain regions with signiﬁcant contributions to the Parkinson's
disease-related cognitive pattern derived from the Groningen data
(PDCPGR)
Brain regiona

Coordinatesb
x

Network-related decreases (negative voxel weights)
Thalamus (mediodorsal nucleus)
0
Caudate nucleus
− 10
Supplementary motor area
2
(rostral, BA 6)
Superior parietal association cortex, BA 5
0
Inferior parietal cortex, BA 7, 40
46
Posterior cingulate cortex, BA 29
0
BA 23
−2

y

Zmaxc

z

− 16
8
14

2 4.35
6 3.32
50 4.11

− 38
− 54
− 52
− 24

54
60
6
28

3.77
3.54
3.64
3.19

Network-related increases (positive voxel weights)
Cerebellum, lobule VI, Crus I
28 − 52 − 38 2.49
Anterior cingulate, BA 32, right
20
42 − 2 2.59
BA 32, left
−18
38
16 2.55
Abbreviation: BA, Brodmann area. aAll brain regions are signiﬁcant
at Z42.44 (Po0.01) and stable on bootstrap resampling (Po 0.01).
b
Montreal Neurological Institute standard space. cMaximum voxel weights
in Z-scores.

correlation between the expression values for this PC and FAB
scores was not signiﬁcant (P = 0.75) in these normal subjects.
Based upon these ﬁndings, the metabolic topography identiﬁed
in the Groningen derivation sample, that is, the ﬁrst PC, was
considered to be a cognition-related spatial covariance pattern and
© 2015 ISCBFM
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Figure 2. (A) A signiﬁcant correlation (r = 0.86, Po 0.001) was found between expression values of the Groningen and original North Shore
Parkinson’s disease (PD)-related cognitive patterns (PDCPGR and PDCPNS) in the derivation cohort of 19 Groningen PD subjects. (B) A similar
correlation (r = 0.82, Po 0.001) was also present in the prospective group of 86 non-demented PD patients from North Shore, including 20
patients with no cognitive impairment (MCI(−)), as well as 34 with single-domain (MCI(s)) and 32 with multiple-domain (MCI(m)) mild cognitive
impairment (MCI).

was accordingly termed PDCPGR. The PDCPGR topography (Table 2)
was characterized by reduced metabolic activity in the caudate
nucleus, mediodorsal thalamus and the presupplementary motor
area (preSMA, Brodmann area (BA) 6), posterior cingulate cortex
(BA 23, 29) and parietal regions (BA 5, 7, 40), with relatively
increased activity in the cerebellum (lobule VI/Crus I) and anterior
cingulate cortex (BA 32). Voxel weights on the pattern were stable
on bootstrap resampling (1000 iterations; |ICV| = 2.75, Po0.01).
To compare the PDCPGR topography with that of the original
North Shore PDCP (termed PDCPNS), we correlated region weights
(loadings) on the two patterns using a voxel-based algorithm.
Indeed, a signiﬁcant voxel-wise correlation (r = 0.52, P o 0.001) was
present between the two PDCP topographies. Moreover, a close
relationship (Figure 2A; r = 0.86, P o 0.001) existed between the
expression values for the two patterns measured in the Groningen
PD subjects. As with PDCPGR expression, PDCPNS values computed
in the same PD subjects (Figure 1C) correlated with corresponding
FAB scores (r = − 0.63, P o 0.005), while an analogous correlation
was not present (P = 0.55) in the healthy control subjects.
Increased PDCPGR Expression is Associated with Greater Cognitive
Impairment
For further validation, we computed PDCPGR expression in
members of a large independent North American PD testing
cohort (n = 86) on a prospective single case basis. This cohort was
comprised of 20 cognitively intact patients (MCI(−)), 34 patients
with single-domain (MCI(s)) and 32 patients with multiple-domain
(MCI(m)) cognitive impairment. A signiﬁcant stepwise increase in
PDCPGR expression was evident (Figure 3) with advancing cognitive
dysfunction across the three MCI subgroups (F(2, 83) = 3.95,
Po0.05; one-way analysis of variance), with higher values in MCI
(m) relative to MCI(−) subjects (Po0.05; post-hoc Tukey’s HSD test).
We also computed PDCPGR expression values in 15 agematched healthy volunteer subjects scanned at the North Shore
site. No signiﬁcant difference was evident for PDCPGR values
measured in healthy volunteer subjects at the two sites (North
Shore: −0.29 ± 0.62; Groningen: 0.0 ± 1.0, P = 0.32; Student’s t-test).
In the North Shore subjects, PDCPGR expression in MCI(−) and MCI
(s) PD subjects did not differ from healthy control values (P40.36;
Student’s t-tests). Network expression was, however, signiﬁcantly
elevated (P o0.01) in the more cognitively impaired MCI(m)
subjects.
Neuropsychological Correlates of PDCPGR Expression
Finally, we examined the relationship between PDCPGR expression
and measures of neuropsychological test performance in the
testing data. Signiﬁcant correlations were found between PDCPGR
© 2015 ISCBFM

Figure 3. Mean Groningen Parkinson’s disease (PD)-related cognitive
pattern (PDCPGR) expression in the derivation cohort of Groningen
PD and healthy controls (HC) groups (left), as well as in the prospective cohort of North Shore PD subgroups and the corresponding
HC group (right). There was a signiﬁcant increase in PDCPGR
expression across the North Shore MCI(−), MCI(s) and MCI(m) PD
groups (F(2, 83) = 3.95, Po 0.05; one-way analysis of variance), with
higher values (Po0.05; Tukey's HSD) in MCI(m) relative to MCI(−)
subjects. **P o0.01, Student’s t-test relative to the North Shore HC
group. MCI, mild cognitive impairment.

expression and performance on the SDMT (r = −0.38, P o 0.005;
Figure 4A), HVOT (r = − 0.28, P o0.05; Figure 4C) and TMT A
(r = 0.40, Po 0.05) and TMT B (r = 0.35, P o 0.05). Similar correlations with test performance were evident with the corresponding
PDCPNS values: SDMT (r = − 0.34, P o 0.005; Figure 4B), HVOT
(r = − 0.26, P o 0.05; Figure 4D) and TMT A: r = 0.31, Po 0.05).
In addition, as in the Groningen sample, PDCPGR and PDCPNS
expression values (Figure 2B) exhibited a close correlation (r = 0.82,
P o0.001) in individual subjects.
DISCUSSION
The ﬁndings suggest that the PDCP, a speciﬁc metabolic
covariance pattern associated with cognitive dysfunction in PD
subjects, is replicable across patient populations. We found that
PDCPGR, the pattern identiﬁed in a new PD derivation cohort
studied at Groningen, the Netherlands resembled the original
Journal of Cerebral Blood Flow & Metabolism (2015), 1478 – 1484
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Figure 4. (A, C) In the North Shore Parkinson’s disease (PD) cohort, signiﬁcant correlations were found between the Groningen PD-related
cognitive pattern (PDCPGR) expression and performance of neuropsychological tests, including the symbol digit modalities test (SDMT;
r = −0.38, P o0.005) and Hooper Visual Organization Test (HVOT; r = − 0.28, P o0.05). (B, D) Similarly, PDCPNS expression was also signiﬁcantly
correlated with SDMT (r = − 0.34, Po0.005) and HVOT (r = − 0.26, P o0.05) performance in the same cohort.

PDCPNS topography identiﬁed in an independent patient sample
studied at North Shore University Hospital in Manhasset, NY, USA.
Indeed, a close correlation was found between the expression
values for the two PDCP topographies in the Groningen sample
and in a large independent PD testing cohort from North Shore.
Moreover, the expression values for both PDCP patterns correlated
similarly with neuropsychological measures of executive functioning in the two PD populations, conﬁrming previous ﬁndings with
the original PDCPNS topography.17,19,21 Finally, similar to the
previously reported ﬁnding in PDCPNS expression,21 stepwise
increases in PDCPGR expression were seen in the testing sample
comprised of non-demented PD patients categorized according to
the degree of cognitive impairment that was present at the time
of imaging. Thus, in aggregate, the data point to the potential
utility of the PDCP as an objective, quantiﬁable biomarker of
cognitive dysfunction in non-demented PD patients.
Cognitive decline in PD probably reﬂects several processes,
including degeneration of ascending cholinergic and dopaminergic
projections as well as intrinsic neocortical changes associated with
localized formation of Lewy bodies and β-amyloid plaque
formation.33 Despite the heterogeneity of cognitive impairment in
PD, the underlying metabolic topography was similar for the two
cognition-related PD networks. Indeed, salient reductions in medial
frontal and parietal metabolic activity, covarying with relative
increases in the cerebellum, were deﬁning features of both PDCP
topographies. That said, PDCPGR was distinguished by contributions
from several regions not represented in the PDCPNS topography,
including metabolic reductions in the caudate nucleus and medial
thalamus and relative increases in the anterior cingulate cortex. By
contrast, the metabolic reductions seen as part of PDCPGR were
localized to relatively posterior premotor regions, whereas in
PDCPNS these changes extended anteriorly into the medial
prefrontal cortex. Moreover, the spatial extent of the medial
parietal node was greater in the original PDCPNS network.
Journal of Cerebral Blood Flow & Metabolism (2015), 1478 – 1484

The differences in topography may be explained by differences
in the derivation of PDCPNS and PDCPGR. To identify a cognitionrelated metabolic pattern in the Groningen sample, we used a
single test, the FAB, to evaluate executive functioning. By contrast,
multiple neuropsychological tests assessing memory as well as
executive function were used in the derivation of the original
PDCP topography. Despite differences in the behavioral covariates
used for PDCP derivation, subject scores for the two topographies
were highly intercorrelated (r40.80) when computed in members
of each PD sample on a prospective single case basis. Moreover,
irrespective of topography, these values exhibited similar correlations with the corresponding cognitive performance indices:
scores on the FAB in the Groningen sample, and on SDMT, HVOT
and TMT A in the North Shore validation sample. We further note
that different PET instruments were used at the two imaging sites.
Even so, differences in scanning platforms likely do not account
for the variation in PDCP topography that was observed across
tomographs, reconstruction algorithms and spatial normalization
techniques.34
Although the FAB is primarily designed to capture frontal
executive dysfunction, it may also be sensitive to cognitive
impairment in the domains of memory and attention.35 This may
explain why the PDCPGR network involves interactions between
frontal and non-frontal regions as mediators of executive
function.36 Furthermore, consistent with the cognition-related
metabolic reductions found in PD using mass-univariate regional
analysis,37,38 we identiﬁed the caudate and the posterior cingulate
cortex as key PDCPGR nodes using an alternative multivariate
network-level approach. That said, given that PDCPGR was
identiﬁed using a different cognitive testing battery than PDCPNS,
it is perhaps not surprising to encounter some variation in the two
network topographies. One such example is the visual association
cortex, which has been noted to undergo progressive metabolic
decline in PD patients progressing to dementia over 2 years of
© 2015 ISCBFM
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follow-up.37 Members of the current Dutch PD cohort were
cognitively normal at the time of scanning. Apart from two
patients who have experienced cognitive decline (Scales for
Outcomes in Parkinson's Disease—Cognition score of 26 and 24 in
2014; cutoff for dementia o 22), these subjects did not report
cognitive issues during the follow-up period (3.6 ± 1.1 years; range
1.3–4.9 years). This may explain why the PDCPGR does not involve
metabolic loss in the visual association cortex—a region closely
associated with incident dementia in PD patients.37,39
Another explanation for the topographical differences between
PDCPGR and PDCPNS may be variation in symptom duration at the
time of imaging in the two cohorts used for pattern identiﬁcation.
PD subjects in the current study had mild motor symptoms and
were scanned relatively early in the disease process (duration:
4.4 ± 3.2 years; range: 1.5–11.5 years). By contrast, the PD subjects
used to identify the original PDCPNS pattern covered a broad
range of disease duration and severity ratings (duration: 11.0 ± 4.6
years; range: 4–17 years). Thus, PDCPGR may capture the metabolic
correlates of the speciﬁc cognitive changes that occur early in the
disease process. These changes are probably because of early
presynaptic dopaminergic deﬁcits and associated changes in
functional connectivity involving mainly the ventral striatum and
the medial prefrontal and anterior cingulate regions. This is
highlighted by attrition of nigral dopaminergic afferents to the
caudate, which has been found in prior studies to correlate with
cognitive functioning in early-stage PD subjects.38,40 By contrast,
the PDCPNS may be more general given that data from PD patients
with a wider range of cognitive dysfunction were used in its
derivation. Regional changes resembling the PDCPNS topography
were seen in a recent univariate comparison of FDG PET scans
from cognitively unimpaired (MCI(−)) and affected (MCI(+)) PD
subjects.39 In comparison to PDCPGR, the PDCPNS emphasized
additional changes in posterior cortical function that occur later in
the disease process. Indeed, in previous longitudinal data, we
found declining metabolic activity in the prefrontal and inferior
parietal lobule with advancing disease.18,20 Although increases in
PDCPNS expression have been associated with reduced dopaminergic input to the caudate nucleus,41 network activity may also
be inﬂuenced by the loss of posterior cortical cholinergic
terminals, resulting in impaired performance on tests of memory,
visuospatial and executive functioning.42,43 Indeed, the risk of
future dementia appears to be higher in patients with cognitive
deﬁcits with posterior cortical substrates.44 In addition, we have
previously noted that the cognitive response to levodopa is
associated with baseline PDCPNS expression levels.19 Whether
analogous network topographies such as PDCPGR exhibit similar
properties is a topic of future study.
CONCLUSION
These data add further support for the use of the PDCP as an
objective biomarker of cognitive change in non-demented PD
subjects. In previous studies, we have found that the PDCP
possesses attributes, such as excellent test–retest reproducibility17
and lack of a discernible placebo effect,19 which make it
potentially useful as an imaging biomarker in clinical trials
directed at the cognitive manifestations of the disease. The
current study provides further support for this idea by demonstrating the stability of the PDCP topography as well as the
consistency of its relationship to cognitive dysfunction across
patient populations.
AUTHOR CONTRIBUTIONS
SKM conceived and designed the study, analyzed and interpreted the data and
drafted and revised the manuscript; CCT analyzed and interpreted the data and
revised the manuscript; LKT acquired the data and revised the manuscript; RAD
acquired the data and revised the manuscript; VD acquired the data and revised

© 2015 ISCBFM

1483
the manuscript; PJM acquired the data and revised the manuscript; KLL
conceived and designed the study, acquired the data and revised the
manuscript; and DE conceived and designed the study, interpreted the data
and revised the manuscript.

DISCLOSURE/CONFLICT OF INTEREST
DE serves on the scientiﬁc advisory board and has received honoraria from the
Michael J Fox Foundation for Parkinson’s Research; is listed as coinventor of patents
re: Markers for use in screening patients for nervous system dysfunction and a
method and apparatus for using same, without ﬁnancial gain; has received research
support from the NIH (NINDS, NIDCD, NIAID) and the Dana Foundation; and has
served as a consultant for Pﬁzer. All other authors declare no competing ﬁnancial
interests.

ACKNOWLEDGMENTS
The authors thank Ms Patricia J Allen and Ms Ivana De Lucia for assistance in data
analysis.

REFERENCES
1 Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 323–332.
2 Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr
Psychiatry 1999; 14: 866–874.
3 Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement
in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc
2000; 48: 938–942.
4 Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients
with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308–312.
5 Muslimovic D, Post B, Speelman JD, De Haan RJ, Schmand B. Cognitive decline in
Parkinson's disease: a prospective longitudinal study. J Int Neuropsychol Soc 2009;
15: 426–437.
6 Aarsland D, Bronnick K, Fladby T. Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep 2011; 11: 371–378.
7 Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter
study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord
2008; 23: 837–844.
8 Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009; 32: 548–557.
9 Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology:
concepts and applications. Ann Neurol 2012; 72: 635–647.
10 Tang CC, Niethammer M, Allen PJ, Leenders KL, Eidelberg D. PET and SPECT
imaging in Parkinsonian syndromes. In: Dierckx RA, Otte A, de Vries EFJ, van
Waarde A, Leenders KL (eds). PET and SPECT in Neurology. Springer-Verlag: Berlin,
Heidelberg, Germany, 2014, pp 619.
11 Teune LK, Renken RJ, Mudali D, De Jong BM, Dierckx RA, Roerdink JB et al. Validation of parkinsonian disease-related metabolic brain patterns. Mov Disord 2013;
28: 547–551.
12 Spetsieris P, Ma Y, Peng S, Ko JH, Dhawan V, Tang CC et al. Identiﬁcation of
disease-related spatial covariance patterns using neuroimaging data. J Vis Exp
2013; 76: e50319.
13 Spetsieris PG, Eidelberg D. Scaled subproﬁle modeling of resting state imaging data
in Parkinson's disease: methodological issues. Neuroimage 2011; 54: 2899–2914.
14 Ma Y, Tang C, Spetsieris P, Dhawan V, Eidelberg D. Abnormal metabolic network
activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab
2007; 27: 597–605.
15 Mure H, Hirano S, Tang CC, Isaias IU, Antonini A, Ma Y et al. Parkinson's disease
tremor-related metabolic network: characterization, progression, and treatment
effects. Neuroimage 2011; 54: 1244–1253.
16 Teune LK, Renken RJ, de Jong BM, Willemsen AT, van Osch MJ, Roerdink JB et al.
Parkinson's disease-related perfusion and glucose metabolic brain patterns
identiﬁed with PCASL-MRI and FDG-PET imaging. Neuroimage Clin 2014; 5:
240–244.
17 Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain
networks associated with cognitive function in Parkinson's disease. Neuroimage
2007; 34: 714–723.
18 Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M et al. Changes in network
activity with the progression of Parkinson's disease. Brain 2007; 130: 1834–1846.
19 Mattis PJ, Tang CC, Ma Y, Dhawan V, Eidelberg D. Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology 2011; 77: 858–865.

Journal of Cerebral Blood Flow & Metabolism (2015), 1478 – 1484

Validation of PD cognition-related pattern
SK Meles et al

1484
20 Tang C, Poston K, Dhawan V, Eidelberg D. Abnormalities in metabolic network
activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci
2010; 30: 1049–1056.
21 Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic
abnormalities associated with mild cognitive impairment in Parkinson disease.
Neurology 2008; 70: 1470–1477.
22 Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at
bedside. Neurology 2000; 55: 1621–1626.
23 Anonymous. Army Individual Test Battery. Manual of Directions and Scoring. War
Department, Adjutant Gernera's Ofﬁce: Washington, DC, USA, 1944.
24 Beck A. Depression Inventory: Manual. Psychological Corporation: San Antonio,
TX, USA, 1987.
25 Delis D, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test: Adult Version. The Psychological Corporation: San Antonio, USA, 1987.
26 Hooper HE. Hooper Visual Organization Test (VOT). Western Psychological Services:
Los Angeles, CA, USA, 1983.
27 Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Lea & Febiger:
Boston, MA, USA, 1978.
28 Smith A. Symbol Digit Modalities Test (SDMT) Manual (revised). Western
Psychological Services: Los Angeles, CA, USA, 1982.
29 Ko JH, Feigin A, Mattis PJ, Tang CC, Ma Y, Dhawan V et al. Network
modulation following sham surgery in Parkinson's disease. J Clin Invest 2014; 124:
3656–3666.
30 Habeck C, Stern Y. Multivariate data analysis for neuroimaging data: overview and
application to Alzheimer's disease. Cell Biochem Biophys 2010; 58: 53–67.
31 Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Thieme:
New York, NY, USA, 1988.
32 Schmahmann JD, Doyon J, Toga AW, Petrides M, Evans AC. MRI Atlas of the
Human Cerebellum. Academic Press: San Diego, CA, USA, 2000.
33 Bohnen NI, Frey KA. Parkinson Dementia: PET ﬁndings. In: Dierckx RA, Otte A, de
Vries EFJ, van Waarde A, Leenders KL (eds). PET and SPECT in Neurology. SpringerVerlag: Berlin Heidelberg, Germany, 2014, pp 359.

Journal of Cerebral Blood Flow & Metabolism (2015), 1478 – 1484

34 Peng S, Ma Y, Spetsieris PG, Mattis P, Feigin A, Dhawan V et al. Characterization of
disease-related covariance topographies with SSMPCA toolbox: effects of spatial
normalization and PET scanners. Hum Brain Mapp 2014; 35: 1801–1814.
35 Cohen OS, Vakil E, Tanne D, Molshatzki N, Nitsan Z, Hassin-Baer S. The frontal
assessment battery as a tool for evaluation of frontal lobe dysfunction in patients
with Parkinson disease. J Geriatr Psychiatry Neurol 2012; 25: 71–77.
36 Alvarez JA, Emory E. Executive function and the frontal lobes: a metaanalytic review. Neuropsychol Rev 2006; 16: 17–42.
37 Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA et al. Cerebral
glucose metabolic features of Parkinson disease and incident dementia:
longitudinal study. J Nucl Med 2011; 52: 848–855.
38 Pappata S, Santangelo G, Aarsland D, Vicidomini C, Longo K, Bronnick K et al. Mild
cognitive impairment in drug-naive patients with PD is associated with cerebral
hypometabolism. Neurology 2011; 77: 1357–1362.
39 Garcia-Garcia D, Clavero P, Gasca Salas C, Lamet I, Arbizu J, Gonzalez-Redondo R
et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive
impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging
2012; 39: 1767–1777.
40 Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF et al. Caudate nucleus:
inﬂuence of dopaminergic input on sequence learning and brain activation in
Parkinsonism. Neuroimage 2004; 21: 1497–1507.
41 Niethammer M, Tang CC, Ma Y, Mattis PJ, Ko JH, Dhawan V et al. Parkinson's
disease cognitive network correlates with caudate dopamine. Neuroimage 2013;
78: 204–209.
42 Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L et al. Dementia
in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716–1722.
43 Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain
Res 2011; 221: 564–573.
44 Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW et al. The
distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the
CamPaIGN cohort. Brain 2009; 132: 2958–2969.

© 2015 ISCBFM

